Skip to Content
Merck
All Photos(1)

Key Documents

SML0130

Sigma-Aldrich

Loxiglumide

≥97% (HPLC)

Synonym(s):

4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-pentanoic acid, CR 1505

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C21H30Cl2N2O5
CAS Number:
Molecular Weight:
461.38
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥97% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: ≥5 mg/mL

storage temp.

2-8°C

SMILES string

CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1

InChI

1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)

InChI key

QNQZBKQEIFTHFZ-UHFFFAOYSA-N

Biochem/physiol Actions

Loxiglumide is a small-molecule antagonist of the cholecystokinin receptor CCKA. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kozo Takase et al.
Nihon rinsho. Japanese journal of clinical medicine, 62(11), 2074-2078 (2004-11-24)
Despite improvement in intensive medical care management, the mortality rate from severe acute pancreatitis is still high. Attempt to reduce the mortality rate, some new drugs were investigated on experimental pancreatitis and clinical cases. There have been several clinical trials
Daisuke Kanemitsu et al.
Pancreas, 32(2), 190-196 (2006-03-23)
Prior studies have indicated that endogenous or exogenous cholecystokinin (CCK) induces transient acinar cell proliferation at about 24 hours after its stimulation. The aims of the present study were to determine the time point when the administration of the CCK-A-receptor
T J Little et al.
Obesity reviews : an official journal of the International Association for the Study of Obesity, 6(4), 297-306 (2005-10-26)
Summary Cholecystokinin (CCK), a peptide that is distributed widely throughout the gastrointestinal tract and the central nervous system, has a number of physiological effects including the stimulation of gallbladder contraction and pancreatic and gastric acid secretion, slowing of gastric emptying
M Rizzo et al.
Journal of pharmaceutical and biomedical analysis, 35(2), 321-329 (2004-04-06)
A high-performance liquid chromatography (HPLC)-method after solid-phase extraction (SPE) has been developed in order to determine a new angiotensin-AT1 antagonist, i.e. CR 3210 (C27H24N8; MW = 460.54), 4-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-3-(2H-tetrazol-5-yl)quinoline in rat plasma and urine after oral administration to Sprague-Dawley rats. CR
L Hidalgo et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 14(5), 519-525 (2002-10-03)
Our aim was determine the relationship between cholecystokinin (CCK)-A receptor blockade, glucose levels, insulin secretion and gastric emptying in humans, and to assess the effect of CCK-A blockade on pancreatic polypeptide secretion. After a 12-h fast, six healthy volunteers were

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service